Renal Cancer
Percutaneous radiofrequency for the treatment of small renal masses: Analysis of outcomes and complications after 10 years of experience.
February 8, 2021
A retrospective study of CT-guided percutaneous irreversible electroporation (IRE) ablation: clinical efficacy and safety.
February 8, 2021
Transcriptome Analyses Identify an RNA Binding Protein Related Prognostic Model for Clear Cell Renal Cell Carcinoma.
February 5, 2021
The Clinical Significance of DNA Damage Repair Signatures in Clear Cell Renal Cell Carcinoma.
February 5, 2021
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.
February 4, 2021
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma.
February 4, 2021
Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials.
February 4, 2021
Mapping the immune environment in clear cell renal carcinoma by single-cell genomics.
February 3, 2021
Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma: A Phase 2 Randomized Study FARETES.
February 2, 2021
Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey.
February 2, 2021
Cellular and physical microenvironments regulate the aggressiveness and sunitinib chemosensitivity of clear cell renal cell carcinoma.
February 2, 2021
The impact of sex and age on distribution of metastases in patients with renal cell carcinoma.
February 1, 2021
Frailty predicts outcome of partial nephrectomy and guides treatment decision towards active surveillance and tumor ablation.
February 1, 2021
Development and validation of a CT-based nomogram for preoperative prediction of clear cell renal cell carcinoma grades.
February 1, 2021
A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol.
January 29, 2021